Merck (MRK) Cost of Revenue (2009 - 2026)

Merck has disclosed Cost of Revenue across 18 years of filings, most recently posting $4.2 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 22.7% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $17.2 billion (up 13.84% YoY), while the FY2025 annual figure was $16.4 billion, up 7.83% from the prior year.
• Cost of Revenue declined to $4.2 billion in Q1 2026, from $5.6 billion in the prior quarter.
• Over the last five years, Cost of Revenue for MRK reached as high as $5.6 billion in Q4 2025 and fell as low as $3.4 billion in Q1 2025.
• The 5-year median for Cost of Revenue is $3.9 billion (2023), against an average of $4.1 billion.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 68.18% — and 2023, when it dropped 27.03%.
• A 5-year view of Cost of Revenue shows it stood at $3.9 billion in 2022, then grew by 0.8% to $3.9 billion in 2023, then fell by 2.15% to $3.8 billion in 2024, then soared by 45.01% to $5.6 billion in 2025, then retreated by 24.43% to $4.2 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.2 billion, $5.6 billion, and $3.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.